According to the "tubulocentric" hypothesis of the glomerular hyperfiltration of diabetes mellitus (DM), tubuloglomerular feedback (TGF) is the critical determinant of the related renal hemodynamic dysfunction. To examine the role of TGF in human type 1 DM, 12 salt-replete healthy (C) and 11 uncomplicated DM individuals underwent measurements of glomerular filtration rate (GFR), renal blood flow (RBF), and lithium-derived absolute "distal" sodium delivery (DDNa). Measurements were made during two 3-h infusions of 0.012 mmol·kg Ϫ1 ·min Ϫ1 L-arginine (ARG) buffered with either equimolar HCl (ARG.HCl) or citric acid (ARG.CITR). Our hypothesis was that changes in TGF signaling would be directionally opposite ARG.HCl vs. ARG.CITR according to the effects of the ARG-buffering anion on DDNa. Similar changes in C and DM followed ARG.CITR, with declines in DDNa (Ϫ0.26 Ϯ 0.07 mmol/min C vs. Ϫ0.31 Ϯ 0.07 mmol/min DM) and increases in RBF (ϩ299 Ϯ 25 vs. ϩ319 Ϯ 29 ml·min Ϫ1 ·1.73 m Ϫ2 ) and GFR (ϩ6.6 Ϯ 0.8 vs. ϩ11.6 Ϯ 1.2 ml·min Ϫ1 ·1.73 m Ϫ2 ). In contrast, with ARG.HCl, DDNa rose in both groups (P ϭ 0.001), but the response was 73% greater in DM (ϩ1.50 Ϯ 0.15 mmol/min C vs. ϩ2.59 Ϯ 0.22 mmol/min DM, P ϭ 0.001). RBF also increased (P ϭ 0.001, ϩ219 Ϯ 20 ml·min Ϫ1 ·1.73 m Ϫ2
(ARG) buffered with either equimolar HCl (ARG.HCl) or citric acid (ARG.CITR). Our hypothesis was that changes in TGF signaling would be directionally opposite ARG.HCl vs. ARG.CITR according to the effects of the ARG-buffering anion on DDNa. Similar changes in C and DM followed ARG.CITR, with declines in DDNa (Ϫ0.26 Ϯ 0.07 mmol/min C vs. Ϫ0.31 Ϯ 0.07 mmol/min DM) and increases in RBF (ϩ299 Ϯ 25 vs. ϩ319 Ϯ 29 ml·min Ϫ1 ·1.73 m Ϫ2 ) and GFR (ϩ6.6 Ϯ 0.8 vs. ϩ11.6 Ϯ 1.2 ml·min Ϫ1 ·1.73 m Ϫ2 ). In contrast, with ARG.HCl, DDNa rose in both groups (P ϭ 0.001), but the response was 73% greater in DM (ϩ1.50 Ϯ 0.15 mmol/min C vs. ϩ2.59 Ϯ 0.22 mmol/min DM, P ϭ 0.001). RBF also increased (P ϭ 0.001, ϩ219 Ϯ 20 ml·min Ϫ1 ·1.73 m Ϫ2 C, ϩ105 Ϯ 14 DM), but ⌬RBF after ARG.HCl was lower vs. ARG.CITR in both groups (P ϭ 0.001). After ARG.HCl, ⌬RBF also was 50% lower in DM vs. C (P ϭ 0.001) and GFR, unchanged in C, declined in DM (Ϫ7.4 Ϯ 0.9 ml·min Ϫ1 ·1.73 m Ϫ2 , P ϭ 0.02 vs. C). After ARG.HCl, unlike ARG.CITR, DDNa increased in C and DM, associated with less ⌬RBF and ⌬GFR vs. ARG.CITR. This suggests that the renal hemodynamic response to ARG is influenced substantially by the opposite actions of HCl vs. CITR on DDNa and TGF. In DM, the association of ARG.HCl-induced exaggerated ⌬DDNa, blunted ⌬RBF, and the decline in GFR vs. C shows an enhanced TGF dependence of renal vasodilatation to ARG, in agreement with a critical role of TGF in DM-related renal hemodynamic dysfunction. type 1 diabetes mellitus; L-arginine; renal hemodynamic function; tubular reabsorption; tubuloglomerular feedback L-ARGININE (ARG) IS CONVERTED to nitric oxide (NO), leading to renal and systemic vasodilatation, thereby having an important influence on vascular endothelial function (1, 4, 7, 11, 19, 20, 31) . In the kidney, in addition to the endothelium-dependent effects on renal vasculature, ARG infusion may influence renal hemodynamic function through changes in the extent to which sodium chloride (NaCl) is delivered to the macula densa (MD), thus modulating tubuloglomerular feedback (TGF) (34, 49, 50) . Renal vasodilatation following a protein meal, an infusion of mixed amino acid, or ARG alone is known to depend critically on the integrity of the TGF mechanism, the abolition of which may prevent any effect (34, 49, 50) . Due to the stimulation of proximal tubular reabsorption (PTR) by the increased amino acid availability, NaCl delivery to the MD (DDNa) would be blunted, thereby reducing TGF signaling. The resulting lowered afferent arteriole resistance (AFR) and increased GFR (34, 49, 50) would therefore cooperate with the NO-dependent renovascular effects of ARG to produce further renal vasodilatation.
In contrast to this, when ARG is administered in a solution containing equimolar amounts of hydrochloric acid (HCl) to buffer such preparations to a physiological pH, PTR is reduced, leading to a rise in urinary Na ϩ excretion (UNaV) in saltreplete humans (1, 4, 19, 20, 31) . Since it is known from animal and human studies of acute metabolic acidosis that a HCl (or NH 4 Cl) load substantially inhibits PTR (14, 36, 37, 40, 47) , the obligatory coinfusion of ARG with the mineral acid HCl would lead to an increase, instead of a decrease, in DDNa, with a reversal of TGF signaling from a reduction to a stimulation. Based on this hypothesis, we recently infused ARG buffered with either equimolar HCl or citric acid (CITR) in healthy humans (4) . Consistent with these premises was the observation that renal hemodynamic responses to ARG.HCl were associated with inhibited PTR, reflected by a marked increase in UNaV and DDNa, the latter based on lithium (Li ϩ ) excretion (4) . In contrast, ARG.CITR administration resulted in the stimulation of PTR, thereby reducing DDNa and UNaV, associated with an enhanced renal vasodilatation compared with ARG.HCl (4). We could not determine the relative contribution to the effect of ARG.HCl on DDNa of the mineral acid load vs. the associated Cl Ϫ anion, although the latter, when infused as KCl, does not affect PTR in rats (14) . Nonetheless, we concluded (4) that switching from ARG.CITR to ARG.HCl blunted the renal hemodynamic response to ARG through the inhibition of PTR resulting in increased DDNa and TGF stimulation.
Despite what is known in healthy humans, the interaction among ARG, buffering anions, and TGF has not been studied in patients with early type 1 diabetes mellitus (DM). Accordingly, we extended our work in healthy humans to patients with uncomplicated type 1 DM, since DM is associated with increased PTR and blunted TGF, which have been implicated in the pathogenesis of the hyperfiltration state characteristic of early type 1 DM ("tubulocentric" hypothesis) (6, 25-27, 43-46). In addition, in experimental and human DM, several stimuli affecting PTR exert exaggerated effects on TGF and renal hemodynamic function, as indicated by the further increase in GFR in salt restriction and decrease on salt repletion ("salt-paradox"), resulting from an increased salt sensitivity of PTR (6, (25) (26) (27) (43) (44) (45) (46) , or by the enhanced renal hemodynamic response to reduced PTR with carbonic anhydrase inhibitors (18) . Our hypothesis was therefore that previously noted differences in renal responsiveness to ARG.HCl vs. ARG.CITR in healthy individuals (4) would be exaggerated in patients with DM, due to a greater sensitivity to HCl-dependent effects on DDNa and TGF and, by consequence, on the renal vasodilatory responses to ARG.
METHODS
Participants. Twelve nonsmoking healthy volunteers (C) and 11 patients with type 1 DM were included ( Table 1 ). All participants provided written informed consent according to the ethical protocols of our Institution. Inclusion criteria were no medication except insulin; no obesity, dyslipidemia, drug or alcohol abuse; and no heart, liver, kidney, endocrine diseases, or atherosclerosis based on history, clinical examination, laboratory screening, electrocardiogram, and heart, abdomen, and vascular ultrasound standard studies. Patients were normotensive [mean sitting systolic pressure (SAP) Ͻ130 mmHg and diastolic pressure (DAP) Ͻ80 mmHg, as measured on three separate visits using an OMRON 705 IT], and their urinary albumin excretion (UAE) did not exceed 20 g/min in a 24-h urine sample. Estimated physical activity was approximately the same between groups (13) .
Experimental design and procedures. Participants underwent two ARG infusion studies in a randomized order with a 4-wk washout between studies. Studies in women were timed to coincide with the follicular phase of the menstrual cycle (4, 29) . For 7 days before each infusion, participants were placed on a controlled daily diet, containing 230 Ϯ 10 mmol Na ϩ , 80 Ϯ 6 mmol K ϩ , and 2,450 Ϯ 70 Kcal (55% carbohydrates, 15% protein, and 30% lipids) and a fixed intake of antioxidants (4, 13, 29) . Adherence to the diet was estimated with a written food record, urinary urea nitrogen excretion (UUN), and UNaV (4, 13, 29) . At 10 p.m. before each study 8 mmol Li2CO3 was administered (4, 29) .
Since a formal euglycemic clamp (8, 39) was not feasible before and during infusion studies, the following procedure was used to reduce the impact of hyperglycemia on results in the DM cohort, as adopted by Tuttle et al. (42) . In DM participants, after receiving only regular insulin for 24 h before the study and fasting overnight, an intravenous infusion of regular insulin (Perfusion Secura, Braun, Germany) was initiated on arrival to the laboratory at 7.00 a.m., and the infusion rate was titrated to maintain a blood glucose (BG) between 4.5 and 5.5 mmol/l for the remainder of the experiment (mean dose 0.19 Ϯ 0.03 mU·kg ). After 2 h on euglycemia, priming doses of inulin (INU) and PAH (10 and 20% solutions, respectively, J. Monico, Venice, Italy) were given, followed by a constant-rate infusion through a venous catheter into the left arm to maintain steady plasma levels between 15 and 200 mg/l, respectively. Another catheter was inserted into the contralateral arm for blood sampling. After a 1-h equilibration and voiding, a 1-h baseline clearance period was performed (4, 29) . An infusion of 0.012 mmol·kg Ϫ1 ·min Ϫ1 ARG was then initiated in the left arm and continued for three 1-h periods using a 1,500 mmol/l ARG solution buffered to pH 7.2 with 1,500 mmol/l of either HCl or CITR (Damor Farmaceutici, Naples, Italy) (4). Tap water (300 ml) was administered hourly. BP was measured oscillometrically every 5 min using an At 60 min of each period, subjects voided and samples of urine for Na ϩ , Cl Ϫ , and Li ϩ were taken, while NO by products NO2ϩNO3 (UNOxV), 8-isoprostane (U8-iso-PGF2␣V), and cGMP (UcGMPV) (4, 13) were measured in baseline urine samples and in those from the entire ARG infusion. Heparinized blood samples were drawn for INU Calculations. Steady-state plasma levels of PAH and INU were maintained throughout the infusion, as indicated by a variability in the baseline period (1.9% PAH, 2.4% INU) very close to that in a duplicate analysis of single plasma samples (1.5 and 2.0%, respectively). Therefore, "effective" renal plasma flow (ERPF) and GFR were estimated using a constant-infusion technique, thus avoiding bladder catheterization (4, 29) . Four ERPF and GFR values in the baseline period and three in each ARG period were obtained by dividing PAH and INU infusion rates (infusate PAH and INU concentrations ϫ infused volume ϫ min Ϫ1 ) for each measured plasma concentration, using mean values in each period to express data. The filtration fraction (FF), RBF, and renal vascular resistances (RVR) were calculated as GFR/ERPF, [ERPF/(1 Ϫ fractional hematocrit)] and MAP/RBF, respectively (4, 5, 25) . Based on standard urinary Li ϩ , Na ϩ , and Cl Ϫ clearances (CNa, CLi, CCl) and GFR, the Li ϩ , Na ϩ , and Cl Ϫ fractional excretion rates (FELi ϭ CLi/GFR, FENa ϭ CNa/GFR, FECl ϭ CCl/GFR), the estimated "proximal" (or before the MD) fractional fluid reabsorption rate [FPR ϭ (GFR Ϫ CLi)/ GFR], and the estimated, absolute "distal" (or before the MD) delivery of NaCl (DDNa ϭ plasma Na ϩ ϫ CLi) were also calculated (4, 5, 22, 23, 29) . Blood and urine HCO 3 Ϫ were calculated from pH and PCO2 according to the Henderson-Hesselbach equation (4).
Analytic methods. Standard methods were used for routine clinical and biochemical measurements. Methods for analysis of Na ϩ , Li ϩ , Cl Ϫ , UUN, PAH, INU, PRA, aldosterone, insulin, blood pH, PCO2, and bicarbonate (HCO 3 Ϫ ), cGMP, UNOxV, urinary albumin, and U8-iso-PGF2␣V were previously described (4, 13, 29) . Plasma ANP (hANP) was measured with a specific IRMA (Shionogi, Osaka, Japan). A radioimmunoassay was used for C-peptide (Linco Research, St. Charles, MO).
Statistics. Data are expressed as means Ϯ SE. Baseline values were compared in C vs. DM with an unpaired Student's t-test. A paired t-test was used for changes in variables from baseline to 3 h and those in urine parameters from baseline to entire urine collection during ARG. Because of a nonnormal distribution, Mann-Whitney U-and Wilcoxon signed rank tests were used for UPGF 2␣V. For BG, plasma Li ϩ , and insulin, MAP, GFR, RBF, RVR, and urinary excretion of Na ϩ , Cl Ϫ , and Li ϩ during ARG, an ANOVA, followed by Bonferroni's test for multiple comparisons, was performed, using SPSS 15.0 software (SPSS, Chicago, IL), according to a "split-plot", factorial design to compare data within each type of treatment, while a randomized block analysis was made within each group of subjects. Factors considered as exerting an interaction in the analysis of data were time, type of treatment (ARG.HCl vs. ARG.CITR) and type of subjects (C vs. DM) (4). All calculated P values were two-tailed, and P Ͻ 0.05 was considered to indicate statistical significance.
RESULTS
Baseline data and metabolic effects of ARG infusion. As expected, baseline creatinine clearance (CCr) and UAE were higher in the DM patients. Also consistent with their diabetic status were glycemic parameters, including fasting BG and HbA1c, and lowered PRA (Table 1) (24, 32) .
As shown in Table 2 , in healthy C participants plasma Na ϩ , BG, ANP, and U8-iso-PGF2␣V remained unchanged during each ARG infusion. C-peptide, insulin, UNOxV, and UcGMPV rose and PRA and plasma Li ϩ declined slowly. As expected, opposite changes in plasma Cl Ϫ and blood HCO 3 Ϫ developed after ARG.CITR vs. ARG.HCl. These changes were identical in the DM group, except for C-peptide, which did not change; insulin, which was already elevated at baseline and remained approximately at the same level due to the constant-rate exogenous insulin infusion; and BG, which was not prevented from increasing, although it did not exceed 6 to 7 mmol/l.
Urinary excretion responses to ARG.HCL and ARG.CITR. After ARG.CITR, UNaV, FENa, FELi, and FECl declined to a similar extent in both groups. Consistent with these trends was the observation that FPR rose equally in DM and C subjects (ϩ0.035 Ϯ 0.029 and ϩ0.033 Ϯ 0.027, P Ͼ 0.05 by type of subjects). Accordingly, as shown in Fig. 1 , the derived estimate of the absolute DDNa decreased to the same extent in C and DM groups (Ϫ0.26 Ϯ 0.07 and Ϫ0.31 Ϯ 0.07 mmol/ min, respectively, P Ͼ 0.05 by type of subjects).
In contrast, after ARG.HCl, FPR decreased and UNaV, FENa, FELi, FECl, and DDNa ( Fig. 1 ) increased markedly in both groups (P Ͻ 0.001 vs. ARG.CITR by type of treatment). All these changes following ARG.HCl were exaggerated in the DM group vs. C (P Ͻ 0.001 by type of subjects), with rises in DDNa ϳ73% greater in the DM vs. C group (Fig. 1) .
Renal hemodynamic responses to ARG.HCL and ARG.CITR. The time course of MAP and renal hemodynamic function during each ARG infusion is summarized in Table 4 .
MAP was similar at baseline in the two groups and was not influenced by ARG except for a small decline in the C group with ARG.CITR (Ϫ1.9 mmHg, P Ͻ 0.05). As expected, baseline GFR, RBF, and FF were higher and RVR lower in the DM group vs. C. Consistent with effects of ARG.CITR on FPR, UNaV, FENa, FECl, FELi, and DDNa, that were similar in the two groups, GFR increased in response to ARG.CITR approximately to the same extent in DM vs. C (P Ͼ 0.05 by type of subjects, Fig. 2 ). With ARG.CITR, RBF also rose (Fig. 3) and RVR declined to the same extent in C and DM (P Ͼ 0.05 by type of subjects).
In contrast, with ARG.HCl, GFR (Fig. 2) did not change in the C group, while in the DM group the exaggerated decline in FPR and rise in UNaV, FENa, FECl, FELi, and DDNa were associated with a significant decline in GFR (P ϭ 0.02 vs. C by type of subjects, Fig. 2 ). With ARG.HCl, RBF (Fig. 3 ) also increased and RVR declined in both groups. However, within each group, such changes were consistently smaller with ARG.HCl than with ARG.CITR (P ϭ 0.001 by type of treatment, Fig. 3 ). In addition to a decline in GFR, ARG.HCl was associated with a blunted vasodilatory response in DM, reflected by 50% smaller increases in RBF and decreases in RVR vs. C (P ϭ 0.001 by type of subjects, Table 4 and Fig. 3) , suggesting an impaired renal hemodynamic response to ARG.HCl based on DM status.
Time course of changes in RBF as related to those in DDNa. At the first hour time point of the ARG.HCl study (Table 3 , Fig. 1 ), DDNa increased in both C and DM (P Ͻ 0.05 from baseline), but to an ϳ0.4 mmol/min greater extent in DM (⌬DDNa ϩ0.91 Ϯ 0.16 mmol/min in DM vs. ϩ0.49 Ϯ 0.14 in C, P Ͻ 0.05). At that time point, ⌬RBF (Table 4 , Fig. 3 ) was still not significant in DM (⌬RBF ϩ29 Ϯ 22 ml·min Ϫ1 ·1.73 m Ϫ2 , P Ͼ 0.05 vs. baseline), while it was already substantial in C (ϩ75 Ϯ 18 ml·min Ϫ1 ·1.73 m Ϫ2 , P Ͻ 0.05 vs. both baseline and DM). In contrast, at the first hour time point, ⌬DDNa in the control group (Table 3 , Fig. 1 ) was greater by 0.5 mmol/ min with ARG-HCL vs. ARG-CITR (⌬DDNa ϩ0.49 Ϯ 0.14 vs. Ϫ0.02 Ϯ 0.08 mmol/min, respectively, P Ͻ 0.05), associated (Table 4 , Fig. 3 ) with a similar, significant (P ϭ 0.05 vs. baseline) ⌬RBF (ϩ75 Ϯ 18 and ϩ92 Ϯ 20 ml·min Ϫ1 ·1.73 m Ϫ2 , respectively, P Ͼ 0.05). At the single second and third hour time points, ⌬DDNa and ⌬RBF results were consistent with the ANOVA of the entire time course.
DISCUSSION
Our previous work has demonstrated that the renal hemodynamic response to ARG in healthy humans is influenced by the accompanying anion (4). In DM individuals, others have suggested that increased PTR leads to blunted TGF signaling, afferent vasodilatation, and a rise in GFR and RBF (6, (25) (26) (27) (43) (44) (45) (46) . We therefore extended our previous work to patients with DM, to test the hypothesis that the effects on PTR of ARG.HCl vs. ARG.CITR would be exaggerated in DM, resulting in enhanced TGF signaling and impaired renal hemodynamic responsiveness to ARG.HCl vs. healthy individuals. Our major findings were 1) ARG.HCl infusion was associated with an exaggerated reduction in PTR and an increase in DDNa in response to ARG.HCl in DM patients vs. C; and 2) in DM, Values are means Ϯ SE. Bicarbonate is calculated from the Henderson-Hesselbach equation (10) . UcGMPV, urinary excretion of cGMP; UNOxV, urinary excretion of NO2ϩNO3; U8-iso-PGF2␣V, urinary excretion of 8-isoprostane. *P Յ 0.001 for DM vs. C at baseline. P Յ 0.05 for DM vs. C at baseline. ¶P Յ 0.05, ANOVA for time-dependent changes. †P Յ 0.001, ANOVA for time-dependent changes. ‡P Յ 0.001 3 h vs. baseline. the exaggerated increase in DDNa and TGF signaling in response to ARG.HCl was associated with a decline in GFR and blunted renal vasodilatation.
According to the tubulocentric hypothesis of hyperfiltration, renal hemodynamic dysfunction related to type 1 DM is initiated by a primary rise in PTR, leading to a reduction in DDNa and inhibition of TGF, afferent vasodilatation, and increased GFR (6, (25) (26) (27) (43) (44) (45) (46) . Due to this primary increase in proximal tubular Na ϩ avidity with increased salt sensitivity of PTR, dietary salt restriction is associated with a further rise in GFR (the salt paradox) (6, (25) (26) (27) (43) (44) (45) (46) . Our baseline measures of PTR are consistent with this previous work, since FPR was higher in DM patients vs. C at the baseline of both the ARG.CITR and ARG.HCl studies (18) .
To elucidate mechanisms underlying differences in tubular function in DM, we administered separate ARG.CITR and ARG.HCl infusions in DM patients and C. We hypothesized that previously noted differences in response to ARG.CITR vs. ARG.HCl in healthy subjects would be exaggerated in patients with DM, since DM influences TGF, leading to renal vasodilatation. Our first major observation is that ARG.HCl infusion was associated with reduced PTR and increased UNaV, FENa, FECl, and DDNa in DM patients and C subjects, in keeping with previous observations (1, 4, 20, 31 ). In addition, consistent with our previous study (4) , switching the ARG-buffering anion from ARG.HCl to the proximally reabsorbed, organic acid CITR (17) reversed the changes in PTR, with modest increases in FPR and reductions in UNaV, FENa, FECl, and DDNa. A further key finding was that, while the tubular responses to ARG.CITR did not differ based on diabetic status, ARG.HCl was followed by an exaggerated inhibition of PTR and increase in DDNa in the DM vs. C group.
The coinfusion of equimolar HCl together with ARG would explain the observed inhibition of PTR during ARG.HCl and the resulting increase in DDNa. An increased UNaV, mainly as a consequence of inhibited proximal NaCl reabsorption, has been firmly established in both animals and humans as an early response to an acute acid load with HCl or NH 4 ϩ Cl (14, 36, 37, 40, 47) . NH 4 ϩ Cl has been commonly used as a convenient substitute for HCl, because of its dissociation as (H ϩ :Cl Ϫ ) plus NH 3 , which is rapidly metabolized (21) . As reviewed by Faroqui et al. (14) , the mineral acid load inhibits PTR through several possible mechanisms, including a decrease in the activity of apical Na ϩ -dependent transporters, such as the proximal tubular Na ϩ /H ϩ exchanger. Interestingly, Cl Ϫ anions are unlikely to be responsible for this effect, since KCl does not influence PTR (14) . In this set of experiments, we cannot exclude the possibility that tubular segments other than PT participated in the reduction in NaCl reabsorption, possibly due to the NO-dependent inhibition of Na ϩ transport by tubular epithelial cells, including those of the thick ascending limb of the loop of Henle, with potential influences on TGF (16) . Regardless of the tubular sites involved, our results support the notion that an alteration in the response of tubular reabsorption to ARG infusion may be elicited in DM, depending on the nature of the coinfused buffering anion.
With ARG.CITR, FPR increased and DDNa declined to the same degree in DM patients vs. C, and changes in GFR, RBF, and RVR were similar in the two groups. Therefore, the renal response to ARG.CITR did not seem to be impaired in DM. In contrast, after ARG.HCl not only the tubular responses but also the associated renal hemodynamic changes were significantly different between DM and C. In healthy individuals, RBF increased in response to ARG.HCl (4, 7, 8, 11, 19, 20, 31) , although to a lesser extent than following ARG.CITR (4), and GFR was unchanged. Our main finding in the DM group was that the exaggerated rise in DDNa in response to ARG.HCl was accompanied by a decline in GFR and blunted renal vasodilatation vs. the C group. Since the different renal hemodynamic effects observed with ARG.CITR vs. ARG.HCl likely reflect the impact on TGF signaling mediated by each attendant anion (4), we suggest that the impaired renal vasodilatation to ARG.HCl in DM was related to the exaggerated inhibition of PTR and increase in DDNa, with an enhanced TGF-mediated modulation of the renal hemodynamic effects of ARG.
The time course for ⌬DDNa as related to renal perfusion deserves some attention. At the first hour of the ARG.HCl study, the DDNa response already was greater in DM vs. C, and associated with a substantial ⌬RBF in C, but not in DM. This indicates, first, that significant renal vasodilatation develops early in ARG.HCl-infused healthy individuals, which fits well with the rapid renal vasoconstriction following NO inhibition with ARG analogs, such as nitro-L-arginine methyl ester (29) ; second, that the augmented sensitivity of PTR, DDNa, and TGF to ARG.HCl could have blunted such an early response in the DM group. However, at that early time point, a difference in ⌬DDNa in the control group between ARG.HCL and ARG.CITR was associated with similar, significant ⌬RBF responses. Therefore, such levels of ⌬DDNa were associated with a blunted RBF response in DM, but not in healthy individuals, suggesting that, in addition to the exaggerated PTR response, other mechanisms could have contributed to the impaired renal Table 3 ). Insets (bottom): ANOVA P values for interactions exerted on ⌬DDNa by type of subjects (C or DM) and type of treatment (ARG.CITR or ARG.HCl). DDNa increased significantly after ARG.HCl and fell after ARG.CITR in both groups (P ϭ 0.001, ANOVA interaction by type of treatment). The negative changes after ARG.CITR were the same in C (Ϫ0.26 Ϯ 0.07 mmol/min at 3 h) and IDDM [Ϫ0.31 Ϯ 0.07 mmol/min at 3 h, P ϭ not significant (NS), ANOVA interaction by type of subjects]. In contrast, after ARG.HCl, ⌬DDNa was greater in DM (ϩ2.59 Ϯ 0.22 mmol/min at 3 h) than in C (ϩ1.50 Ϯ 0.15 mmol/min at 3 h, P ϭ 0.001, ANOVA interaction by type of subjects). At 1-h time point of the ARG.HCl study, DDNa increased significantly (P Ͻ 0.05 from baseline) in both C and DM, but to an ϳ0.4 mmol/min greater extent in DM (⌬DDNa ϩ0.91 Ϯ 0.16 mmol/min DM vs. ϩ0.49 Ϯ 0.14 mmol/min C, P Ͻ 0.05). At the same 1-h time point in C, ⌬DDNa was greater by 0.5 mmol/min with ARG-HCL vs. ARG-CITR (⌬DDNa ϩ0.49 Ϯ 0.14 mmol/min vs. Ϫ0.02 Ϯ 0.08, respectively, P Ͻ 0.05). At the 2-and 3-h single time points, DDNa results were consistent with the ANOVA of the whole time course.
hemodynamic response to ARG.HCl in DM, such as a defective endothelium-dependent response of renal vasculature to ARG ("renal endothelial dysfunction") (11) .
Caution should be used, however, in this interpretation, as well as in the definition of a renal endothelial dysfunction based on the renal responses to ARG (11) . Independent of the superimposed changes in TGF related to the buffering anion, the overall renal effects of ARG infusion result from a complex interplay between a number of mechanisms, ultimately leading to renal vasodilatation and a rise in RBF in C and DM with both ARG preparations (1, 4, 7, 8, 11, 19, 20, 31) . The involved mechanisms, sometimes operating in opposite directions and with different timing, essentially include the increased availability of the amino acid ARG at the PT, which would facilitate vasodilatation by lowering DDNa and TGF (34, 43, 49, 50) and ARG-induced intrarenal NO production. The latter leads to a variety of renal physiological changes, such as 1) the NOdependent inhibition of Na ϩ reabsorption by tubular epithelial cells, including those of the thick ascending limb of the loop of Henle, with potential influences on TGF (16); 2) the NOdependent dilatation of renal vasculature, also mediated by counteracting endogenous vasoconstrictors, such as angiotensin II and endothelin (6, 16, 29) ; and 3) the MD effects, which further enhance vasodilatation by reducing autoregulation of AFR and the efficiency of TGF signaling (2, 6) . In addition, since TGF occurs within minutes and resets within 1 h (12), the influence of the relatively small ⌬DDNa as that seen in the first hour may have been obscured by some TGF resetting.
The observed variations in reabsorption and renal hemodynamics were remarkably progressive along each 3-h ARG experiment. This time course was most likely related to the slow rate of ARG infusion, adopted to prevent any significant systemic acid-base change due to the substantial acid or alkali load provided by ARG.HCL or ARG.CITR, respectively. However, other reasons could have contributed in DM to a slower development of maximal ARG effects. First, with ARG.HCl, Cl Ϫ could have accumulated over the course of the infusion, leading to later changes in DDNa and TGF. Given the early increase in DDNa and FECl, this seems unlikely. Second, since the intrarenal RAS is expected to be activated at baseline in the DM group (6, 24, 32, 39) , the modulation of the RAS by the rapid increase in DDNa could be early vs. the NOdependent vascular effects of ARG, leading to a delayed vasodilatation in DM. Third, the time required for ARGderived endothelial NO production through NO synthase could also be delayed in the DM group, as an expression of renal endothelial dysfunction (11) .
Regardless of the complexity of the potentially involved changes, data of ARG infusion as a whole show in DM vs. C an accentuated reduction in tubular NaCl reabsorption with ARG when buffered with HCl, which would indicate an abnormal tubular sensitivity to the mineral acid load in DM. This was associated with a reduction in GFR in the presence of a still substantial ARG-induced renal vasodilatation, although ⌬RBF to ARG.HCl was impaired in DM vs. C. This association quite closely reproduces the previous observation that the lower GFR on salt repletion vs. salt restriction (salt paradox of DM) was related to an exaggerated tubular response to NaCl, as an expression of a heightened salt sensitivity of the PTR (6, (25) (26) (27) (43) (44) (45) (46) . Taken together, our data in DM indicate first, that, as hypothesized, tubular reabsorption also is more sensitive to an acute HCl load; and second, that the renal hemodynamic responses to ARG.HCl are critically influenced by the changes in reabsorption and DDNa, thus supporting the concept that TGF plays a crucial role in the regulation of renal hemodynamic function in DM.
While the mechanism underlying the enhanced PTR characteristic of early type 1 DM remains unknown, it has been suggested that the intrarenal RAS may play a pivotal role. Patients with DM exhibit evidence of intrarenal RAS activation and low circulating levels of RAS mediators, referred to as the paradox of the low-renin state in DM (6, 24, 32, 39) . A baseline stimulated intrarenal RAS would be further activated by the increased DDNa after ARG.HCl, leading to a "sensitized" glomerular hemodynamic response to the augmented TGF under the influence of intrarenal angiotensin II (28) and accounting, in part, for the enhanced renal hemodynamic response to amino acids in ACE-inhibited DM patients (38) . Intrarenal RAS activation could therefore have participated in the blunted renal hemodynamic effects of ARG.HCl in DM vs. C, in contrast to the lack of differences during the ARG.CITR infusion, which resulted in similar, modest decreases in DDNa in the two groups.
In addition to the RAS, renal vasoconstriction is increased by oxidative stress, as reflected by the elevated U8-iso-PGF2␣V (10) . Oxidative stress may influence renal responses to ARG in DM through suppression of renal endothelial function (11) and enhanced TGF signaling (48) . We cannot exclude the possibility that higher levels of U8-iso-PGF2␣V in the DM group potentiated the effect of TGF when activated by ARG.HCl, leading to a blunted vasodilatory response. In contrast, this mechanism does not seem to be significant without an activated TGF, as was after ARG.CITR, when the C and DM groups responded in a similar manner.
From a vasodilatory perspective, the elevated UNOxV indicates increased baseline NO production in DM, which may impair renal hemodynamic autoregulation either by directly reducing AFR, by blunting the effect of TGF on AFR, or by attenuating the effect of vasoconstrictors (2, 6) . Despite this, UNO X V and UcGMPV were normally stimulated by both ARG.HCl and ARG.CITR in DM. Therefore, at least within the limits of UNO X V as a reflection of ARG-induced renal NO production and of UcGMPV as a marker of the renal vascular and tubular response to NO, respectively, it seems unlikely that NO and cGMP were responsible for the observed differences after ARG.HCl vs. ARG.CITR.
Previous studies comparing renal hemodynamic responses to a protein load or amino acid infusion in DM vs. healthy individuals have yielded conflicting results, possibly because these studies have not controlled for the effects of tubular reabsorption and TGF (15, 30, 35, 38, 41, 42) . As a consequence, while TGF is a determinant of renal vasodilatation in response to an oral protein load or amino acid infusion in experimental models (34, 49, 50) , less is known about TGF responses in humans. Previous work in healthy individuals demonstrated a renal vasodilatory response to an acetatebuffered amino acid solution, which was blunted by the coinfusion of intravenous NaCl and ECFV expansion (9) . The authors attributed this to inhibition of PTR, leading to increased DDNa and enhanced TGF signaling (9) . Dietary Na .73 m Ϫ2 in C), the ⌬GFR time course was not significantly different between DM and C (P ϭ NS, ANOVA interaction by type of subjects). In contrast, after ARG.HCl, changes in GFR were not significant in C and negative in DM (Ϫ7.4 Ϯ 0.9 ml·min Ϫ1 ·1.73 m Ϫ2 at 3 h), with a P ϭ 0.02 ANOVA interaction by type of subjects.
intake similarly influences renal vasodilatation responses to ARG or mixed amino acid infusion (1, 33) . In our participants, prestudy dietary Na ϩ intake was carefully controlled and saline infusions were avoided to limit the effect of factors that are known to influence PTR and TGF signaling. Because protein intake (estimated with UUN) and variations in insulin, C-peptide, PRA, UcGMPV, and UNOxV responses were the same in the ARG.HCl and ARG.CITR infusion studies, other factors that influence the renal responses to ARG infusion also were limited. Furthermore, changes in acid-base status are unlikely to have accounted for responses to ARG, since much larger pH effects than those observed in our cohort are required to acutely influence RBF and GFR (3). Our findings therefore suggest that the differences in PTR and renal hemodynamic function were due to differences in the response to ARG.HCl vs. ARG.CITR, rather than salt intake, RAS activation, systemic acid-base balance, or changes in ECFV.
Our study has some limitations. First, the sample size was small, which may have limited our ability to detect some differences in renal hemodynamic parameters. We attempted to minimize the effect of the small sample size by utilizing homogeneous study groups and by careful prestudy dietary preparation. We also decreased variability by using a study design that allowed each subject to act as his or her own control. Second, insulin and ambient hyperglycemia can influence vasodilatation and TGF (6, 8, 39) . We controlled for these factors through the use of an insulin infusion, resulting in similar circulating insulin levels and BG not exceeding 7 mmol/l. It was therefore unlikely that these factors played an important role in our study. Third, PTR was estimated on the basis of Li ϩ excretion, which remains the most common and accepted method to determine PTR in humans. Since ϳ7% of filtered Li ϩ may be reabsorbed beyond PT (5, 22, 23) , caution is needed in interpreting our results. However, "distal" Li ϩ reabsorption would have been minimized in our Na-replete and water-loaded subjects (5, 22, 23) . In addition, the extent to which FELi was affected by ARG.HCl vs. ARG.CITR (ϩ40% vs. Ϫ13% in C, ϩ79% vs. Ϫ16% in DM) indicates an unequivocal inhibition by ARG.HCl of tubular reabsorption proximal to the MD, which was exaggerated based on diabetic Table 4 ). Symbols on the top of the 1-h bars represent the significance of ⌬RBF from baseline at this single time point ( ¶P Ͻ 0.05 vs. baseline; ϱP Ͻ 0.05, C-ARG.HCl vs. DM-ARG.HCl; see Table 4 ). Insets (bottom): ANOVA P values for interactions exerted on ⌬RBF time course by type of subjects (C or DM) and type of treatment (ARG.CITR or ARG.HCl). ⌬RBF were positive after ARG.CITR and ARG.HCl, with changes in RBF significantly lower after ARG.HCl than after ARG.CITR (P ϭ 0.001, ANOVA interaction by type of treatment) in both C and DM. After ARG.CITR, ⌬RBF was essentially the same in C (ϩ299 Ϯ 25 ml·min Ϫ1 ·1.73 m Ϫ2 at 3 h) as was in DM (ϩ319 Ϯ 29 ml·min Ϫ1 ·1.73 m Ϫ2 at 3 h, P ϭ NS, ANOVA interaction by type of subjects). In contrast, after ARG.HCl, ⌬RBF was much lower in DM (ϩ105 Ϯ 14 ml·min ·1.73 m Ϫ2 at 3 h, P ϭ 0.001, ANOVA interaction by type of subjects). At 1-h time point of the ARG.HCl study, ⌬RBF was still not significant in DM (⌬RBF ϩ29 Ϯ 22 ml·min Ϫ1 ·1.73 m Ϫ2 , P ϭ NS), but it was substantial in C (ϩ75 Ϯ 18 ml·min Ϫ1 ·1.73 m Ϫ2 , P Ͻ 0.05 vs. both baseline and DM). In the control group, ⌬RBF after ARG.HCl was similar as that following ARG-CITR (ϩ92 Ϯ 20 ml·min Ϫ1 ·1.73 m Ϫ2 , P Ͼ 0.05). At the 2-and 3-h single time points, RBF results were consistent with the ANOVA of the whole time course. status. Nonetheless, future studies are needed with loop diuretics or TGF inhibitors, such as adenosine type 1 receptor antagonists, to isolate the relative contributions of proximal vs. distal tubular reabsorption as well as intrarenal hemodynamic factors that regulate renal responses to ARG.
In conclusion, in healthy humans and in DM patients renal hemodynamic responses to ARG are influenced substantially by the nature of the anions used to buffer ARG solutions. We suggest that this effect is mediated by the directionally opposite changes in DDNa and TGF signaling, according to the tubular actions of HCl vs. CITR. Because of the exaggerated inhibition of PTR and increase in DDNa after ARG.HCl in DM vs. C individuals, associated with blunted renal vasodilatation and decline in GFR, the dependence of renal vasodilatation to ARG on tubular mechanisms and TGF appears to be enhanced in DM, in keeping with a prominent role of TGF in DM-related renal hemodynamic dysfunction. 
